[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for dual GLP-1/GIP receptor agonist enicepatide in people living with type 2 diabetes and overweight or obesity

Phase 2positiveenicepatidePositive

AI Analysis

Summary

Roche announced positive Phase II results for enicepatide (CT-388), a dual GLP-1/GIP receptor agonist, showing dose-dependent reductions in HbA1c and body weight in adults with type 2 diabetes and overweight or obesity. The highest dose (24 mg) achieved 2.65% HbA1c reduction and 15.5% mean weight loss at 48 weeks, with 90% of patients reaching target HbA1c levels.

Clinical Trial Data

Phase

Phase 2

Primary Endpoint

Met

Outcome Details

Met both primary endpoints with dose-dependent reductions in HbA1c and body weight. At 24 mg dose: 2.65% HbA1c reduction, 90% achieved HbA1c ≤6.5%, 62% achieved normoglycemia (HbA1c <5.7%), 15.5% mean weight loss at 48 weeks.

Importance:7/10

Sentiment:

0.85

Phase 2 dataGLP-1/GIP agonisttype 2 diabetesobesitypositive resultsweight loss

Related Companies

$RHHBY

Read the original article

Published by GlobeNewswire Pharma on September 22, 2026 5:00 AM

Read Original